Work

Association ofMGMTGene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-typeIDHGlioblastoma

Year: 2021

Type: article

Abstract: BACKGROUND: -methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). PATIENTS AND METHODS: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. RESULTS: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. CONCLUSION: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.

Source: Anticancer Research

DOI: 10.21873/anticanres.15490

Authors: MOONSIK KIM, JIHWAN YOO, JONG HEE CHANG, SE HOON KIM

Institutions: Kyungpook National University, Kyungpook National University Chilgok Hospital, Yonsei University, Severance Hospital, Yonsei University Health System

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4200606830

FWCI: 0.695

Cites: 33

Cited by: 7

Related to: 10